A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

Kurokawa T, Iinuma T, Ebisu H, Yanagidaira T, Inaba Y, Fujiwara T, Hattori Y, Fukazawa T, Aoki T, Koseki H, Hanaoka H, Hanazawa T, Motohashi S

Open source

DOI
10.1371/journal.pone.0342387
Published
2026
Container
PloS one
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0342387,
  title = {A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.},
  author = {Kurokawa T and Iinuma T and Ebisu H and Yanagidaira T and Inaba Y and Fujiwara T and Hattori Y and Fukazawa T and Aoki T and Koseki H and Hanaoka H and Hanazawa T and Motohashi S},
  year = {2026},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0342387},
  url = {https://doi.org/10.1371/journal.pone.0342387}
}

RIS

TY  - JOUR
TI  - A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.
AU  - Kurokawa T
AU  - Iinuma T
AU  - Ebisu H
AU  - Yanagidaira T
AU  - Inaba Y
AU  - Fujiwara T
AU  - Hattori Y
AU  - Fukazawa T
AU  - Aoki T
AU  - Koseki H
AU  - Hanaoka H
AU  - Hanazawa T
AU  - Motohashi S
PY  - 2026
JO  - PloS one
DO  - 10.1371/journal.pone.0342387
UR  - https://doi.org/10.1371/journal.pone.0342387
ER  - 

APA

T, K., T, I., H, E., T, Y., Y, I., T, F., Y, H., T, F., T, A., H, K., H, H., T, H., & S, M. (2026). A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.. PloS one. https://doi.org/10.1371/journal.pone.0342387

Source records